• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组合使用盒式给药和微采样以减少用于食蟹猴、野生型小鼠和人 FcRn 转基因小鼠的抗体药代动力学研究中的动物使用量。

Combination of cassette-dosing and microsampling for reduced animal usage for antibody pharmacokinetics in cynomolgus monkeys, wild-type mice, and human FcRn transgenic mice.

机构信息

Research Division, Chugai Pharmaceutical Co. Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka, 412-8513, Japan.

出版信息

Pharm Res. 2021 Apr;38(4):583-592. doi: 10.1007/s11095-021-03028-6. Epub 2021 Mar 29.

DOI:10.1007/s11095-021-03028-6
PMID:33782838
Abstract

PURPOSE

The aim of this study was to develop a useful antibody PK evaluation tool using a combination of cassette-dosing and microsampling in mice and monkeys in order to reduce the number of animals used.

METHODS

Cetuximab, denosumab, infliximab, and a mixture of the three antibodies, i.e., cassette-dosing, were administered intravenously to cynomolgus monkeys, C57BL/6J mice, and homozygous human neonatal Fc-receptor transgenic (Tg32) mice. Mouse blood was collected from one animal continuously via the jugular vein at nine points.

RESULTS

In cynomolgus monkeys, infliximab showed faster elimination in the cassette-dosing group than in the single-dose group. Anti-drug antibody production was observed, but the PK parameters of the clearance and distribution volume were similar in both groups. In C57BL/6J and Tg32 mice, each of the plasma concentrations-time profiles after cassette-dosing were similar to those after single dosing. PK evaluation using a combination of cassette-dosing and microsampling in mice may reduce the number of mice used by approximately 90% compared with the conventional method.

CONCLUSIONS

The combination of antibody cassette-dosing and microsampling is a promising PK evaluation method as a high-throughput and reliable with reduced numbers of mice and cynomolgus monkeys.

摘要

目的

本研究旨在开发一种使用组合式盒式给药和微采样的方法,用于小鼠和猴子中的抗体 PK 评估,以减少动物使用数量。

方法

西妥昔单抗、地舒单抗、英夫利昔单抗和三种抗体混合物(即盒式给药)通过静脉内给予食蟹猴、C57BL/6J 小鼠和纯合人新生 Fc 受体转基因(Tg32)小鼠。从小鼠颈静脉连续采集一只动物的血液,共采集 9 个点。

结果

在食蟹猴中,与单次剂量组相比,英夫利昔单抗在盒式给药组中表现出更快的消除。观察到抗药物抗体的产生,但清除率和分布容积的 PK 参数在两组中相似。在 C57BL/6J 和 Tg32 小鼠中,每个盒式给药后的血浆浓度-时间曲线与单次给药后相似。与传统方法相比,使用组合式盒式给药和微采样进行的小鼠 PK 评估可能将小鼠的使用数量减少约 90%。

结论

抗体盒式给药和微采样的组合是一种有前途的 PK 评估方法,具有高通量、高可靠性,同时减少了小鼠和食蟹猴的使用数量。

相似文献

1
Combination of cassette-dosing and microsampling for reduced animal usage for antibody pharmacokinetics in cynomolgus monkeys, wild-type mice, and human FcRn transgenic mice.组合使用盒式给药和微采样以减少用于食蟹猴、野生型小鼠和人 FcRn 转基因小鼠的抗体药代动力学研究中的动物使用量。
Pharm Res. 2021 Apr;38(4):583-592. doi: 10.1007/s11095-021-03028-6. Epub 2021 Mar 29.
2
Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models.新型 Fc 工程化单克隆和多特异性抗体在食蟹猴和人源化 FcRn 转基因小鼠模型中的药代动力学。
MAbs. 2020 Jan-Dec;12(1):1829337. doi: 10.1080/19420862.2020.1829337.
3
Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.人源FcRn转基因小鼠模型在单克隆抗体人药代动力学早期评估和预测的药物研发中的应用
MAbs. 2016 Aug-Sep;8(6):1064-78. doi: 10.1080/19420862.2016.1193660. Epub 2016 May 27.
4
Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.单克隆抗体的线性药代动力学参数在同种内和不同的药理学靶标之间相似:使用群体建模方法在人、食蟹猴和 hFcRn Tg32 转基因小鼠之间进行比较。
MAbs. 2018 Jul;10(5):751-764. doi: 10.1080/19420862.2018.1462429. Epub 2018 May 14.
5
Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.对人抗制瘤素M单克隆抗体的Fc区域进行修饰,以提高对FcRn受体的亲和力并延长食蟹猴体内的半衰期。
Basic Clin Pharmacol Toxicol. 2017 Jul;121(1):13-21. doi: 10.1111/bcpt.12761. Epub 2017 Mar 8.
6
Application of blood microsampling in cynomolgus monkey and demonstration of equivalent monoclonal antibody PK parameters compared to conventional sampling.血液微采样在食蟹猴中的应用及与常规采样相比单克隆抗体 PK 参数的等效性验证。
Pharm Res. 2021 May;38(5):819-830. doi: 10.1007/s11095-021-03044-6. Epub 2021 May 12.
7
Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.生成并鉴定了一种高亲和力抗人 FcRn 抗体 rozanolixizumab,不同分子形式对降低血浆 IgG 浓度的影响。
MAbs. 2018 Oct;10(7):1111-1130. doi: 10.1080/19420862.2018.1505464. Epub 2018 Sep 12.
8
Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities.灵长类动物与FcRn转基因小鼠中IgG抗体的药代动力学之间的相关性揭示了一种具有预测能力的啮齿动物模型。
MAbs. 2013 May-Jun;5(3):397-405. doi: 10.4161/mabs.23836. Epub 2013 Apr 2.
9
Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies.用于治疗性抗体药代动力学评估的人源FcRn转基因小鼠
Methods Mol Biol. 2016;1438:103-14. doi: 10.1007/978-1-4939-3661-8_6.
10
Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.研究新生Fc受体结合亲和力和抗治疗性抗体对食蟹猴体内人源化抗肿瘤坏死因子-α IgG单克隆抗体药代动力学影响的建模方法。
Eur J Pharm Sci. 2014 Jan 23;51:51-8. doi: 10.1016/j.ejps.2013.08.033. Epub 2013 Aug 31.

引用本文的文献

1
Microsampling in toxicology studies - maximising the scientific, business and 3Rs advantages.毒理学研究中的微量采样——最大化科学、商业及3R优势。
Toxicol Res (Camb). 2025 Mar 31;14(2):tfaf045. doi: 10.1093/toxres/tfaf045. eCollection 2025 Apr.
2
Flycodes enable simultaneous preclinical analysis for dozens of antibodies in single cassette-dosed mice.飞行编码能够在单次给予卡式试剂的小鼠中对数十种抗体进行同步临床前分析。
Proc Natl Acad Sci U S A. 2025 Mar 25;122(12):e2426481122. doi: 10.1073/pnas.2426481122. Epub 2025 Mar 17.
3
Preclinical Pharmacokinetics and Biodistribution of LR004, a Novel Antiepidermal Growth Factor Receptor Monoclonal Antibody.

本文引用的文献

1
A Physiologically-Based Pharmacokinetic Model for the Prediction of "Half-Life Extension" and "Catch and Release" Monoclonal Antibody Pharmacokinetics.用于预测“半衰期延长”和“捕获和释放”单克隆抗体药代动力学的基于生理的药代动力学模型。
CPT Pharmacometrics Syst Pharmacol. 2020 Sep;9(9):534-541. doi: 10.1002/psp4.12547. Epub 2020 Aug 17.
2
Predicting Method for the Human Plasma Concentration-Time Profile of a Monoclonal Antibody from the Half-life of Non-human Primates.从非人灵长类动物半衰期预测单克隆抗体的人体血浆浓度-时间曲线的方法。
Biol Pharm Bull. 2020;43(5):823-830. doi: 10.1248/bpb.b19-01042.
3
Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues.
新型抗表皮生长因子受体单克隆抗体LR004的临床前药代动力学与生物分布
Molecules. 2024 Jan 22;29(2):545. doi: 10.3390/molecules29020545.
4
Development of a New Method to Evaluate the Biodistribution of Antibodies Using Non-Radioactive Metal Labeling and Inductively Coupled Plasma Mass Spectrometry.利用非放射性金属标记和电感耦合等离子体质谱法开发一种新的抗体生物分布评估方法。
Pharm Res. 2023 Jul;40(7):1807-1819. doi: 10.1007/s11095-023-03541-w. Epub 2023 Jun 2.
5
Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper.非人类灵长类动物在生物制剂的 PKPD 评估中的应用:减少、优化和替代的需求和选择。BioSafe 白皮书。
MAbs. 2022 Jan-Dec;14(1):2145997. doi: 10.1080/19420862.2022.2145997.
在小鼠血清和组织中,一种替代抗 IL-36R 单克隆抗体拮抗剂的 ADME 特性的临床前特征。
MAbs. 2020 Jan-Dec;12(1):1746520. doi: 10.1080/19420862.2020.1746520.
4
Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.抗体 Fc 工程改造增强新生儿 Fc 受体结合和延长循环半衰期。
MAbs. 2019 Oct;11(7):1276-1288. doi: 10.1080/19420862.2019.1633883. Epub 2019 Jul 18.
5
Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.抗体工程技术生成长效抗 C5 再循环抗体 SKY59。
PLoS One. 2018 Dec 28;13(12):e0209509. doi: 10.1371/journal.pone.0209509. eCollection 2018.
6
Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.用于筛选单克隆抗体先导候选物的药代动力学风险降低工具。
MAbs. 2017 Jul;9(5):756-766. doi: 10.1080/19420862.2017.1323160. Epub 2017 May 2.
7
Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.人源FcRn转基因小鼠模型在单克隆抗体人药代动力学早期评估和预测的药物研发中的应用
MAbs. 2016 Aug-Sep;8(6):1064-78. doi: 10.1080/19420862.2016.1193660. Epub 2016 May 27.
8
An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.一种Fc工程方法,可调节抗体依赖性细胞因子释放而不改变细胞杀伤功能。
MAbs. 2015;7(3):494-504. doi: 10.1080/19420862.2015.1022692.
9
Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.人源FcRn转基因小鼠作为单克隆抗体药代动力学筛选工具的应用。
Xenobiotica. 2014 Dec;44(12):1127-34. doi: 10.3109/00498254.2014.941963. Epub 2014 Jul 17.
10
One mouse, one pharmacokinetic profile: quantitative whole blood serial sampling for biotherapeutics.一只小鼠,一种药代动力学特征:生物治疗药物的定量全血连续采样
Pharm Res. 2014 Jul;31(7):1823-33. doi: 10.1007/s11095-013-1286-y. Epub 2014 Jan 24.